Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
J Mol Cell Cardiol ; 186: 111-124, 2024 01.
Article in English | MEDLINE | ID: mdl-38039845

ABSTRACT

The mechanistic target of rapamycin (mTOR) is evolutionarily conserved from yeast to humans and is one of the most fundamental pathways of living organisms. Since its discovery three decades ago, mTOR has been recognized as the center of nutrient sensing and growth, homeostasis, metabolism, life span, and aging. The role of dysregulated mTOR in common diseases, especially cancer, has been extensively studied and reported. Emerging evidence supports that mTOR critically regulates innate immune responses that govern the pathogenesis of various cardiovascular diseases. This review discusses the regulatory role of mTOR in macrophage functions in acute inflammation triggered by ischemia and in atherosclerotic cardiovascular disease (ASCVD) and heart failure with preserved ejection fraction (HFpEF), in which chronic inflammation plays critical roles. Specifically, we discuss the role of mTOR in trained immunity, immune senescence, and clonal hematopoiesis. In addition, this review includes a discussion on the architecture of mTOR, the function of its regulatory complexes, and the dual-arm signals required for mTOR activation to reflect the current knowledge state. We emphasize future research directions necessary to understand better the powerful pathway to take advantage of the mTOR inhibitors for innovative applications in patients with cardiovascular diseases associated with aging and inflammation.


Subject(s)
Cardiovascular Diseases , Heart Failure , Humans , Sirolimus/pharmacology , Stroke Volume , TOR Serine-Threonine Kinases/metabolism , Inflammation , Macrophages/metabolism , Mechanistic Target of Rapamycin Complex 1
2.
J Mol Cell Cardiol ; 159: 62-79, 2021 10.
Article in English | MEDLINE | ID: mdl-34139235

ABSTRACT

Monocytes and macrophages are cellular forces that drive and resolve inflammation triggered by acute myocardial ischemia. One of the most important but least understood regulatory mechanisms is how these cells sense cues from the micro-milieu and integrate environmental signals with their response that eventually determines the outcome of myocardial repair. In the current study, we investigated if the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) plays this role. We present evidence that support a robustly activated mTORC1 pathway in monocytes and macrophages in the infarcting myocardium.. Specific mTORC1 inhibition transformed the landscape of cardiac monocytes and macrophages into reparative cells that promoted myocardial healing. As the result, mTORC1 inhibition diminished remodeling and reduced mortality from acute ischemia by 80%. In conclusion, our data suggest a critical role of mTORC1 in regulating the functions of cardiac monocytes and macrophages, and specific mTORC1 inhibition protects the heart from inflammatory injury in acute ischemia. As mTOR/mTORC1 is a master regulator that integrates external signals with cellular responses, the study sheds light on how the cardiac monocytes and macrophages sense and respond to the ischemic environment..


Subject(s)
Heart/physiopathology , Mechanistic Target of Rapamycin Complex 1/metabolism , Myocardial Ischemia/metabolism , Myocardium/metabolism , Phagocytes/metabolism , Ventricular Remodeling/physiology , Animals , Macrophages/metabolism , Mice , Myocardial Infarction/metabolism , Signal Transduction/physiology
4.
Circulation ; 137(24): 2613-2634, 2018 06 12.
Article in English | MEDLINE | ID: mdl-29437120

ABSTRACT

BACKGROUND: Myocardium irreversibly injured by ischemic stress must be efficiently repaired to maintain tissue integrity and contractile performance. Macrophages play critical roles in this process. These cells transform across a spectrum of phenotypes to accomplish diverse functions ranging from mediating the initial inflammatory responses that clear damaged tissue to subsequent reparative functions that help rebuild replacement tissue. Although macrophage transformation is crucial to myocardial repair, events governing this transformation are poorly understood. METHODS: Here, we set out to determine whether innate immune responses triggered by cytoplasmic DNA play a role. RESULTS: We report that ischemic myocardial injury, along with the resulting release of nucleic acids, activates the recently described cyclic GMP-AMP synthase-stimulator of interferon genes pathway. Animals lacking cyclic GMP-AMP synthase display significantly improved early survival after myocardial infarction and diminished pathological remodeling, including ventricular rupture, enhanced angiogenesis, and preserved ventricular contractile function. Furthermore, cyclic GMP-AMP synthase loss of function abolishes the induction of key inflammatory programs such as inducible nitric oxide synthase and promotes the transformation of macrophages to a reparative phenotype, which results in enhanced repair and improved hemodynamic performance. CONCLUSIONS: These results reveal, for the first time, that the cytosolic DNA receptor cyclic GMP-AMP synthase functions during cardiac ischemia as a pattern recognition receptor in the sterile immune response. Furthermore, we report that this pathway governs macrophage transformation, thereby regulating postinjury cardiac repair. Because modulators of this pathway are currently in clinical use, our findings raise the prospect of new treatment options to combat ischemic heart disease and its progression to heart failure.


Subject(s)
Cytosol/enzymology , DNA/metabolism , Macrophages/enzymology , Myocardial Infarction/enzymology , Myocardium/metabolism , Nucleotidyltransferases/metabolism , Signal Transduction , Animals , Macrophages/pathology , Mice , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Myocardium/pathology , Nucleotidyltransferases/genetics , Ventricular Remodeling
6.
Expert Rev Cardiovasc Ther ; 12(9): 1087-98, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25047512

ABSTRACT

Heart failure has become a huge public health problem. The treatment options for heart failure, however, are considerably limited. The significant disparity between the scope of a prominent health problem and the restricted means of therapy propagates heart failure epidemics. Delineating novel mechanisms of heart failure is imperative. Emerging evidence suggests that epigenetic regulation may take part in the pathogenesis of heart failure. Epigenetic regulation involves DNA and histone modifications that lead to changes in DNA-based transcriptional programs without altering the DNA sequence. Although more and more mechanisms are being discovered, the best understood epigenetic modifications are achieved through covalent biochemical reactions including histone acetylation, histone methylation and DNA methylation. Connecting environmental stimuli with genomic programs, epigenetic regulation remains important in maintaining homeostases and the pathogeneses of diseases. This review summarizes the most recent developments regarding individual epigenetic modifications and their implications in the pathogenesis of heart failure. Understanding this strategically important mechanism is potentially the key for developing powerful interventions in the future.


Subject(s)
DNA Methylation , Epigenesis, Genetic , Heart Failure/physiopathology , Acetylation , Animals , Heart Failure/genetics , Heart Failure/therapy , Histones/metabolism , Humans
8.
J Am Heart Assoc ; 2(2): e000016, 2013 Apr 08.
Article in English | MEDLINE | ID: mdl-23568341

ABSTRACT

BACKGROUND: Mechanical assist device therapy has emerged recently as an important and rapidly expanding therapy in advanced heart failure, triggering in some patients a beneficial reverse remodeling response. However, mechanisms underlying this benefit are unclear. METHODS AND RESULTS: In a model of mechanical unloading of the left ventricle, we observed progressive myocyte atrophy, autophagy, and robust activation of the transcription factor FoxO3, an established regulator of catabolic processes in other cell types. Evidence for FoxO3 activation was similarly detected in unloaded failing human myocardium. To determine the role of FoxO3 activation in cardiac muscle in vivo, we engineered transgenic mice harboring a cardiomyocyte-specific constitutively active FoxO3 mutant (caFoxO3(flox);αMHC-Mer-Cre-Mer). Expression of caFoxO3 triggered dramatic and progressive loss of cardiac mass, robust increases in cardiomyocyte autophagy, declines in mitochondrial biomass and function, and early mortality. Whereas increases in cardiomyocyte apoptosis were not apparent, we detected robust increases in Bnip3 (Bcl2/adenovirus E1B 19-kDa interacting protein 3), an established downstream target of FoxO3. To test the role of Bnip3, we crossed the caFoxO3(flox);αMHC-Mer-Cre-Mer mice with Bnip3-null animals. Remarkably, the atrophy and autophagy phenotypes were significantly blunted, yet the early mortality triggered by FoxO3 activation persisted. Rather, declines in cardiac performance were attenuated by proteasome inhibitors. Consistent with involvement of FoxO3-driven activation of the ubiquitin-proteasome system, we detected time-dependent activation of the atrogenes program and sarcomere protein breakdown. CONCLUSIONS: In aggregate, these data point to FoxO3, a protein activated by mechanical unloading, as a master regulator that governs both the autophagy-lysosomal and ubiquitin-proteasomal pathways to orchestrate cardiac muscle atrophy.


Subject(s)
Forkhead Transcription Factors/metabolism , Heart Failure/therapy , Heart-Assist Devices , Membrane Proteins/metabolism , Mitochondrial Proteins/metabolism , Myocytes, Cardiac/metabolism , Ventricular Remodeling/physiology , Animals , Atrophy , Autophagy , Disease Models, Animal , Forkhead Box Protein O3 , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/physiology , Heart Transplantation , Humans , Membrane Proteins/genetics , Membrane Proteins/physiology , Mice , Mice, Transgenic , Mitochondrial Proteins/genetics , Mitochondrial Proteins/physiology , Myocardium/metabolism , Myocardium/pathology , Myocytes, Cardiac/pathology , Myocytes, Cardiac/physiology , Proteasome Endopeptidase Complex/physiology , Signal Transduction , Ubiquitin-Protein Ligase Complexes/physiology
9.
Autophagy ; 7(9): 1078-9, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21593592

ABSTRACT

The heart is a highly plastic organ. In a recent study, we found that autophagy is a required element in load-induced cardiomyocyte growth; when autophagy is suppressed, the heart does not grow. Conversely, afterload stress triggers a transient increase in cardiomyocyte autophagic activity which settles to a new--higher--baseline once the heart has re-achieved steady-state size. Our work went on to decipher the role of histone deacetylases in this biology.


Subject(s)
Autophagy , Heart/growth & development , Animals , Apoptosis Regulatory Proteins/metabolism , Autophagy/drug effects , Heart/anatomy & histology , Heart/drug effects , Histone Deacetylase Inhibitors/pharmacology , Humans , Mice , Myocytes, Cardiac/cytology , Myocytes, Cardiac/drug effects , Organ Size/physiology
10.
Proc Natl Acad Sci U S A ; 108(10): 4123-8, 2011 Mar 08.
Article in English | MEDLINE | ID: mdl-21367693

ABSTRACT

Histone deacetylases (HDACs) regulate cardiac plasticity; however, their molecular targets are unknown. As autophagy contributes to pathological cardiac remodeling, we hypothesized that HDAC inhibitors target autophagy. The prototypical HDAC inhibitor (HDACi), trichostatin A (TSA), attenuated both load- and agonist-induced hypertrophic growth and abolished the associated activation of autophagy. Phenylephrine (PE)-triggered hypertrophy and autophagy in cultured cardiomyocytes were each blocked by a panel of structurally distinct HDAC inhibitors. RNAi-mediated knockdown of either Atg5 or Beclin 1, two essential autophagy effectors, was similarly capable of suppressing ligand-induced autophagy and myocyte growth. RNAi experiments uncovered the class I isoforms HDAC1 and HDAC2 as required for the autophagic response. To test the functional requirement of autophagic activation, we studied mice that overexpress Beclin 1 in cardiomyocytes. In these animals with a fourfold amplified autophagic response to TAC, TSA abolished TAC-induced increases in autophagy and blunted load-induced hypertrophy. Finally, we subjected animals with preexisting hypertrophy to HDACi, finding that ventricular mass reverted to near-normal levels and ventricular function normalized completely. Together, these data implicate autophagy as an obligatory element in pathological cardiac remodeling and point to HDAC1/2 as required effectors. Also, these data reveal autophagy as a previously unknown target of HDAC inhibitor therapy.


Subject(s)
Autophagy/drug effects , Cardiomegaly/prevention & control , Histone Deacetylase Inhibitors/pharmacology , Acetylation , Animals , Cardiomegaly/chemically induced , Cardiomegaly/immunology , Phenylephrine/pharmacology , Rats , Rats, Sprague-Dawley
11.
Curr Hypertens Rep ; 11(6): 406-11, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19895751

ABSTRACT

Autophagy is an evolutionarily conserved catabolic pathway of lysosome-dependent turnover of damaged proteins and organelles. When nutrients are in short supply, bulk removal of cytoplasmic components by autophagy replenishes depleted energy stores, a process critical for maintaining cellular homeostasis. However, prolonged activation of autophagic pathways can result in cell death. Longstanding evidence has linked the stimulation of lysosomal pathways to pathologic cardiac remodeling and a number of cardiac diseases, including heart failure and ischemia. Only recently, however, has work begun to parse cytoprotective autophagy from autophagy that contributes to disease pathogenesis. Current thinking suggests that the effects of autophagy exist on a continuum, with the eliciting triggers, the duration and amplitude of autophagic flux, and possibly the targeted intra-cellular cargo as critical determinants of the end result. Deciphering how autophagy participates in basal homeostasis of the heart, in aging, and in disease pathogenesis may uncover novel insights with clinical relevance in the treatment of heart disease.


Subject(s)
Autophagy/physiology , Heart Diseases/physiopathology , Myocytes, Cardiac/physiology , Ventricular Remodeling/physiology , Apoptosis , Heart/physiology , Heart/physiopathology , Heart Failure/physiopathology , Homeostasis , Humans , Myocardial Ischemia/physiopathology
12.
Am J Physiol Cell Physiol ; 295(1): C257-67, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18495808

ABSTRACT

In two-dimensional (2-D) culture systems, we have previously shown that cleaved two-chain high-molecular-weight kininogen (HKa) or its domain 5 induced apoptosis by disrupting urokinase plasminogen activator (uPA) receptor (uPAR)-integrin signal complex formation. In the present study, we used a three-dimensional (3-D) collagen-fibrinogen culture system to monitor the effects of HKa on tube formation. In a 3-D system, HKa significantly inhibited tube and vacuole formation as low as 10 nM, which represents 1.5% of the physiological concentration of high-molecular-weigh kininogen (660 nM), without apparent apoptosis. However, HKa (300 nM) completely inhibited tube formation and increased apoptotic cells about 2-fold by 20-24 h of incubation. uPA-dependent ERK activation and uPAR internalization regulate cell survival and migration. In a 2-D system, we found that exogenous uPA-induced ERK phosphorylation and uPAR internalization were blocked by HKa. In a 3-D system, we found that not only uPA-uPAR association but also the activation of ERK were inhibited by HKa. HKa disrupts the uPA-uPAR complex, inhibiting the signaling pathways, and also inhibits uPAR internalization and regeneration to the cell surface, thereby interfering with uPAR-mediated cell migration, proliferation, and survival. Thus, our data suggest that the suppression of ERK activation and uPAR internalization by HKa contributes to the inhibition of tube formation. We conclude that in this 3-D collagen-fibrinogen gel, HKa modulates the multiple functions of uPAR in endothelial cell tube formation, a process that is closely related to in vivo angiogenesis.


Subject(s)
Endothelial Cells/physiology , Kininogens/physiology , Receptors, Cell Surface/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Apoptosis , Cell Adhesion , Cell Movement , Cells, Cultured , Endothelial Cells/drug effects , Endothelium, Vascular/cytology , Extracellular Signal-Regulated MAP Kinases/physiology , Humans , Kininogens/pharmacology , Phosphorylation , Receptors, Urokinase Plasminogen Activator , Signal Transduction
13.
Expert Opin Drug Saf ; 7(1): 53-67, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18171314

ABSTRACT

Recent work has demonstrated the importance of chromatin remodeling, especially histone acetylation, in the control of gene expression in the heart. Studies in preclinical models suggest that inhibition of histone deacetylase (HDAC) activity - using compounds that show promise in ongoing oncology trials - blunts pathologic growth of cardiac myocytes. Indeed, small-molecule inhibitors of HDACs are members of an evolving class of pharmacologic agents in development for the treatment of several diseases. If proved effective in the treatment of heart disease, HDAC inhibitors could have a significant impact on public health, as cardiovascular disease remains the leading cause of death in the US. This paper reviews understanding of the mechanisms of action of HDAC inhibitors in the heart and summarizes emerging data regarding their effects on disease-related cardiac remodeling and function.


Subject(s)
Heart Diseases/drug therapy , Heart Diseases/enzymology , Histone Deacetylase Inhibitors , Animals , Clinical Trials as Topic/methods , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Histone Deacetylases/metabolism , Humans
14.
Proc Natl Acad Sci U S A ; 104(51): 20517-22, 2007 Dec 18.
Article in English | MEDLINE | ID: mdl-18077353

ABSTRACT

Insulin resistance and metabolic syndrome are rapidly expanding public health problems. Acting through the PI3K/Akt pathway, insulin and insulin-like growth factor-1 (IGF-1) inactivate FoxO transcription factors, a class of highly conserved proteins important in numerous physiological functions. However, even as FoxO is a downstream target of insulin, FoxO factors also control upstream signaling elements governing insulin sensitivity and glucose metabolism. Here, we report that sustained activation of either FoxO1 or FoxO3 in cardiac myocytes increases basal levels of Akt phosphorylation and kinase activity. FoxO-activated Akt directly interacts with and phosphorylates FoxO, providing feedback inhibition. We reported previously that FoxO factors attenuate cardiomyocyte calcineurin (PP2B) activity. We now show that calcineurin forms a complex with Akt and inhibition of calcineurin enhances Akt phosphorylation. In addition, FoxO activity suppresses protein phosphatase 2A (PP2A) and disrupts Akt-PP2A and Akt-calcineurin interactions. Repression of Akt-PP2A/B interactions and phosphatase activities contributes, at least in part, to FoxO-dependent increases in Akt phosphorylation and kinase activity. Resveratrol, an activator of Sirt1, increases the transcriptional activity of FoxO1 and triggers Akt phosphorylation in heart. Importantly, FoxO-mediated increases in Akt activity diminish insulin signaling, as manifested by reduced Akt phosphorylation, reduced membrane translocation of Glut4, and decreased insulin-triggered glucose uptake. Also, inactivation of the gene coding for FoxO3 enhances insulin-dependent Akt phosphorylation. Taken together, this study demonstrates that changes in FoxO activity have a dose-responsive repressive effect on insulin signaling in cardiomyocytes through inhibition of protein phosphatases, which leads to altered Akt activation, reduced insulin sensitivity, and impaired glucose metabolism.


Subject(s)
Forkhead Transcription Factors/metabolism , Insulin Resistance , Myocytes, Cardiac/metabolism , Protein Phosphatase 2/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/metabolism , Animals , Calcineurin/metabolism , Forkhead Transcription Factors/pharmacology , Heart , Insulin/pharmacology , Mice , Myocytes, Cardiac/drug effects , Phosphoprotein Phosphatases/antagonists & inhibitors , Phosphorylation , Protein Phosphatase 2/metabolism , Rats
15.
J Cell Physiol ; 200(3): 360-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15254963

ABSTRACT

In a two-dimensional (2D) culture dish, the major activity of endothelial cells is proliferation with limited morphological change. When cultured in a three-dimensional (3D) collagen gel matrix, endothelial cells undergo a series of morphological changes starting with development of intracellular vacuoles and followed by cell elongation. Adjacent cells then coalesce to form tube-like structures. This process mimics the steps of capillary formation during angiogenesis. Using this model, we investigated the roles of extracellular signal-regulated kinase (ERK) and p38 MAP kinase (p38) in the tube formation from human umbilical vein endothelial cells (HUVEC). Proliferating HUVEC gradually lost their ability to divide after being transferred to 3D collagen matrices, where differentiation became the dominant cellular activity. The transition from proliferation to the differentiation state was accompanied by a drastic reduction of cyclin-dependent kinases CDC2, CDK4, and retinoblastoma (Rb) protein, but the expression of cyclin-dependent kinase inhibitor, p27kip1, was increased. Inhibition of p38 by SB203580 partially prevented these changes and increased the proliferation rate of HUVEC. However, cells under this condition exhibited unusually elongated cell bodies, and they were unable to coalesce to form tube structures. Inhibition of ERK neither affected the cell proliferation rate nor the expression levels of cell cycle regulators, but it completely blocked tube formation by inducing apoptosis, a finding different from the best-known role of ERK in cell proliferation in the 2D cell culture systems. We conclude that the major function of ERK is to maintain cell viability while p38 plays multiple roles in controlling cell proliferation, viability, and morphogenesis during tube formation.


Subject(s)
Collagen Type I/physiology , Endothelium, Vascular/growth & development , Extracellular Matrix/physiology , Mitogen-Activated Protein Kinases/physiology , Apoptosis/drug effects , Blotting, Western , Caspase Inhibitors , Caspases/physiology , Cell Differentiation , Cell Division/drug effects , Cell Line , Cell Survival , Endothelium, Vascular/cytology , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Gels , Gene Expression Regulation/drug effects , Humans , Imidazoles/pharmacology , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Pyridines/pharmacology , Umbilical Veins/cytology , p38 Mitogen-Activated Protein Kinases
16.
Circ Res ; 94(9): 1227-34, 2004 May 14.
Article in English | MEDLINE | ID: mdl-15044324

ABSTRACT

Cleaved high molecular weight kininogen (HKa) has been shown to inhibit in vivo neovascularization and induce apoptosis of endothelial cells. We have shown that HKa-induced apoptosis correlated with its antiadhesive effect and was regulated by extracellular matrix (ECM) proteins. In this study, we identified the urokinase-type plasminogen activator receptor (uPAR) as a target of HKa activity at the endothelial cell surface. Anti-uPAR antibodies blocked the apoptotic effect of HKa. Further studies revealed that uPAR formed a signaling complex containing integrin alpha(v)beta3 or alpha5beta1, caveolin, and Src kinase Yes in endothelial cells. HKa physically disrupted the formation of this complex in a manner that paralleled its apoptotic effect. For the first time, our results provide a mechanistic explanation for the previous observation that HKa selectively induces apoptosis of endothelial cells grown on vitronectin, but not cells grown on fibronectin. These data also resolve the controversial role of uPAR in mediating the apoptotic and antiadhesive activities of HKa.


Subject(s)
Apoptosis/drug effects , Kininogen, High-Molecular-Weight/physiology , Receptors, Cell Surface/physiology , src-Family Kinases , Antibodies, Monoclonal/pharmacology , Apoptosis/physiology , Caveolin 1 , Caveolins/physiology , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cells, Cultured , Endothelial Cells , Endothelium, Vascular , Extracellular Matrix Proteins/physiology , Fibroblast Growth Factor 2/pharmacology , Fibronectins/pharmacology , Humans , Integrin alpha5beta1/physiology , Integrin alphaVbeta3/physiology , Kininogen, High-Molecular-Weight/pharmacology , Macromolecular Substances , Phosphatidylinositol Diacylglycerol-Lyase/pharmacology , Protein-Tyrosine Kinases/physiology , Proto-Oncogene Proteins/physiology , Proto-Oncogene Proteins c-yes , Receptors, Cell Surface/drug effects , Receptors, Urokinase Plasminogen Activator , Umbilical Veins , Vitronectin/pharmacology
17.
J Cell Biochem ; 89(3): 622-32, 2003 Jun 01.
Article in English | MEDLINE | ID: mdl-12761895

ABSTRACT

We previously reported that cleaved high molecular weight kininogen (HKa) and its domain 5 (D5) inhibit critical steps required for angiogenesis and in vivo neovascularization (Colman et al. 2000: Blood 95:543-550). We have further shown that D5 is able to induce apoptosis of endothelial cells, which may represent a critical part of the anti-angiogenic activity of HKa and D5 (Guo et al. 2001: Arterioscler Thromb Vasc Biol 21:1427-1433). In this study, we demonstrate that HKa- and D5-induced apoptosis is closely correlated with their anti-adhesive effect. An important new finding is that the apoptotic activity of HKa and D5 is highly regulated by their interactions with different extracellular matrix (ECM) proteins. HKa inhibited cell adhesion to vitronectin (Vn, 90%) and gelatin (Gel) (40%), but it had no apparent effect on cell adhesion to fibronectin (Fn). D5 showed a similar pattern on cell adhesion but was less potent than HKa. HKa induced apoptosis of endothelial cells grown on Vn and Gel but not cells grown on Fn which closely parallels with its anti-adhesive potency. Further results revealed that the anti-adhesive effect and the apoptotic effect of HKa are associated with its ability to inhibit phosphorylation of focal adhesion kinase (FAK) and paxillin, two important signal molecules required for cell adhesion and cell viability. We conclude that the anti-adhesive activity of HKa and D5 is responsible for their apoptotic effect and that Vn is likely an ECM component that mediates the effect of HKa and D5.


Subject(s)
Apoptosis , Extracellular Matrix/physiology , Kininogens/physiology , Cell Adhesion , Cytoskeletal Proteins/metabolism , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Humans , Kininogens/chemistry , Molecular Weight , Paxillin , Phosphoproteins/metabolism , Phosphorylation , Protein-Tyrosine Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...